Floatz logo

ag-120

Refractory

Institute of Hematology & Blood Diseases Hospital, ChinaN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

20 Active assets in the Refractory cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
UNC Lineberger Comprehensive Cancer Center
Phase 2B
Cyclophosphamide
The Second Hospital of Shandong University
Phase 2B
Pembrolizumab
Memorial Sloan Kettering Cancer Center
Phase 2CCC
Epirubicin
Memorial Sloan Kettering Cancer Center
Phase 2CCC
Pomalidomide
UNC Lineberger Comprehensive Cancer Center
Phase 2CCC

View all 33 →

Same molecule, other indications

ag-120 is also rated in:

acute myeloid leukemia with multilineage dysplasiaDormant
BB
Indicative ·
66 / 100
View asset →
IDH1 MutationDormant
BB
Indicative ·
64 / 100
View asset →
myeloproliferative neoplasmDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →